Rabbit anti-Human CD62E/E-Selectin Monoclonal Antibody for Flow Cytometry - P16581

Core Product Specifications and Parameters

Biological Background: E-selectin Function and Localization

• E-selectin (CD62E) is a cell-surface glycoprotein belonging to the selectin family of adhesion molecules, encoded by the SELE gene.
• Functions in immunoadhesion by mediating the tethering and rolling of blood neutrophils on cytokine-activated endothelial cells through interaction with P-selectin glycoprotein ligand-1 (SELPLG/PSGL1).
• Has been implicated in capillary morphogenesis, suggesting a role beyond leukocyte recruitment.
• Structurally, it contains an N-terminal C-type lectin domain, an EGF-like domain, and multiple Sushi (complement control protein) repeats, along with a transmembrane helix.
• Localizes to the cell membrane, consistent with its role in cell adhesion and signaling.
• Features calcium-dependent binding, disulfide bonds, and glycosylation, critical for its adhesive functions.

Experimental Guidance and Technical Tips

• The immunogen corresponds to the extracellular domain (aa 22–230), targeting the ligand-binding region; thus, this conjugated antibody is well-suited for detecting surface-expressed E-selectin by flow cytometry.
• For flow cytometry, consider using an appropriate isotype control and titrating the antibody to determine the optimal staining concentration for your experimental system.
• As E-selectin expression is induced on endothelial cells upon inflammatory stimuli, validate staining in relevant activated cell models such as HUVECs treated with TNF-α or IL-1β.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides a one-stop supply of IVD raw materials, including high-quality anti-CD62E/E-Selectin antibodies like this conjugate, to support research into endothelial biology, inflammation, and leukocyte adhesion. Beyond individual antibody products, our portfolio encompasses validated antibody pairs, bulk ancillary reagents, and sourcing services for rare targets, helping diagnostic manufacturers accelerate development from concept to clinic.